Given that reducing HOOK1 levels leads to the occurrence of proteotoxic stress and compromises the survival of CSCs, inhibiting this protein could be a promising therapeutic strategy in ovarian tumors. This evidence concerns the gene HOOK1 and ovarian neoplasm.